• user warning: Table './fnndrupaldev/term_node' is marked as crashed and last (automatic?) repair failed query: SELECT t.* FROM term_node r INNER JOIN term_data t ON r.tid = t.tid INNER JOIN vocabulary v ON t.vid = v.vid WHERE r.vid = 468459 ORDER BY v.weight, t.weight, t.name in /var/www/www.fnno.com/htdocs/modules/taxonomy/taxonomy.module on line 617.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT COUNT(sid) AS count FROM sessions WHERE timestamp >= 1419269512 AND uid = 0 in /var/www/www.fnno.com/htdocs/includes/session.inc on line 111.
  • user warning: Table './fnndrupaldev/sessions' is marked as crashed and last (automatic?) repair failed query: SELECT DISTINCT u.uid, u.name, s.timestamp FROM users u INNER JOIN sessions s ON u.uid = s.uid WHERE s.timestamp >= 1419269512 AND s.uid > 0 ORDER BY s.timestamp DESC in /var/www/www.fnno.com/htdocs/modules/user/user.module on line 765.

Bearish Moving Average Cross by Auxilium Pharmaceuticals (AUXL)

Published on Thu, 03/28/2013 - 11:13
By Adrienne Chilton

Today, shares of Auxilium Pharmaceuticals (NASDAQ:AUXL) have fallen below their 10-day MA of $17.47 on a volume of 173K shares. Swing traders may find an opportunity for a short position, as such a crossover often suggests lower prices in the near term.

There is potential upside of 38.7% for shares of Auxilium Pharmaceuticals based on a current price of $17.30 and an average consensus analyst price target of $24.00. The stock should find initial resistance at its 50-day moving average (MA) of $17.77 and further resistance at its 200-day MA of $21.20.

Over the past year, Auxilium Pharmaceuticals has traded in a range of $16.25 to $29.37 and is now at $17.30, 6% above that low. In the last five trading sessions, the 50-day moving average (MA) has fallen 0.4% while the 200-day MA has slid 0.3%.

Auxilium Pharmaceuticals Inc. develops and commercializes pharmaceutical products that target urologic and sexual health disorders. The company's marketed product ,TESTIM, is a proprietary, topical 1% testosterone gel indicated for the treatment of hypogonadism.

By Adrienne Chilton
achilton@fnno.com

Latest News from FNNO

Shares of Telekomunikasi Indonesia Recei...

Up 1.9% to $45.42, Telekomunikasi Indonesia (NYSE:TLK), is one of today's notable mover ...

Discovery Communications Makes a Move: D...

Down 1.9% to $34.75, Discovery Communications (NASDAQ:DISCA), is one of today's notable ...

Buyers Accumulate Shares of Kla-Tencor, ...

Kla-Tencor (NASDAQ:KLAC) is a company whose shares are active, trading 1.9% higher to $ ...

Shares of Industrias Bachoco Under Press...

One of today's notable stocks in decline is Industrias Bachoco (NYSE:IBA), down 1.9% to ...

The Williams Cos Makes a Move: Down 1.9%...

The Williams Cos (NYSE:WMB), a company whose shares are moving quickly, is trading 1.9% ...

Shares of AngloGold Ashanti Under Pressu...

AngloGold Ashanti (NYSE:AU) is one of today's biggest movers, down 1.9% to $8.56. The ...

Take-Two Interactive Software Shares Cli...

Up 2.0% to $28.68, Take-Two Interactive Software (NASDAQ:TTWO), is one of today's notab ...

Shares of FirstEnergy Under Pressure, Do...

FirstEnergy (NYSE:FE) is one of today's notable stocks in decline, down 2.0% to $37.96. ...